Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration

Published: Tuesday, November 30, 2010
Last Updated: Tuesday, November 30, 2010
Bookmark and Share
Selcia Limited announced a drug discovery collaboration agreement with Gilead Sciences Inc. Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.

Dr. William Lee, Senior Vice President, Research at Gilead Sciences, commented: “We are pleased to announce the continued research collaboration with Selcia in this very important therapeutic area for Gilead.  Scientists from both companies have interacted well together and have made successful progress against some difficult targets. We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future”.

Commenting on the announcement, Selcia’s Managing Director, Dr. Hans Fliri said: “We are delighted to build on our strong collaborative relationship with Gilead in this challenging research area and important therapeutic indication.  This represents a significant step forward in the development of Selcia’s Discovery services and further cements our position as a strategic and trusted partner for integrated drug discovery.  We look forward to continuing to support Gilead in their search for new drugs to treat liver diseases and in fulfilling their longer term objectives”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia and Cantab Announce Drug Discovery Collaboration
Partnership to accelerate Cantab’s programme to develop improved antibiotics for multidrug resistant Gram-negative bacterial infections.
Thursday, September 05, 2013
Selcia Introduces New Prolyl Isomerase Screening Service
Selcia Limited has announced the launch of a new platform to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (“PPIases”).
Friday, February 01, 2013
Selcia and NeuroVive to Develop New Mitochondrial Medicines
Selcia Limited and NeuroVive Pharmaceutical AB have signed a research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology.
Monday, October 10, 2011
Selcia and ExonHit Therapeutics Announce Successful Fragment Screening Collaboration
Successful completion of a drug discovery project with ExonHit Therapeutics using Selcia’s fragment screening technology.
Thursday, April 21, 2011
Selcia Appoints Simon Saxby as CEO and Andreas Rummelt to its Board
Simon Saxby brings successful leadership and executive management experience to the role of Selcia’s CEO and Andreas is recognized as a global expert in drug development and will further enhance the strategic strength of Selcia’s Board.
Thursday, February 24, 2011
Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration Around Chronic Pain
Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.
Thursday, November 25, 2010
Simon Saxby Joins Board at Selcia
Selcia Limited, a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Monday, June 28, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos